Patient Guide: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 80 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05063162
Status: 🟢 Enrolling Now
Condition: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Phase: PHASE3

Where You Can Participate

This study is available at 80 locations across the country.

Top locations include:
  • • Scottsdale, Arizona
  • • Palo Alto, California
  • • Aurora, Colorado
  • • And 77 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) - Join Clinical Trial NCTNCT05063162

How to Join This Clinical Trial - NCTNCT05063162

Learn how to participate in this PHASE3 trial studying an investigational therapy for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD). This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05063162 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 80 locations. Find a study site near you:

Clinical Research Site

Scottsdale, Arizona 85259-5452 - United States

Status: RECRUITING

Clinical Research Site

Palo Alto, California 94304 - United States

Status: RECRUITING

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: RECRUITING

Clinical Research Site

Washington, District of Columbia 20057 - United States

Status: RECRUITING

Clinical Research Site

Jacksonville, Florida 32224-1865 - United States

Status: WITHDRAWN

Clinical Research Site

Tampa, Florida 33612 - United States

Status: RECRUITING

Clinical Research Site

Peoria, Illinois 61637 - United States

Status: RECRUITING

Clinical Research Site

Kansas City, Kansas 66160 - United States

Status: RECRUITING

Clinical Research Site

Baltimore, Maryland 21287 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02114-3117 - United States

Status: RECRUITING

And 70 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD):

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships